Catherine Oakman

1.8k total citations
32 papers, 1.3k citations indexed

About

Catherine Oakman is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Catherine Oakman has authored 32 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 20 papers in Cancer Research and 11 papers in Molecular Biology. Recurrent topics in Catherine Oakman's work include Breast Cancer Treatment Studies (14 papers), HER2/EGFR in Cancer Research (12 papers) and Cancer Treatment and Pharmacology (10 papers). Catherine Oakman is often cited by papers focused on Breast Cancer Treatment Studies (14 papers), HER2/EGFR in Cancer Research (12 papers) and Cancer Treatment and Pharmacology (10 papers). Catherine Oakman collaborates with scholars based in Italy, United States and Australia. Catherine Oakman's co-authors include Angelo Di Leo, Laura Biganzoli, Giuseppe Viale, Libero Santarpia, Silvia Cappadona, Leonardo Tenori, Claudio Luchinat, Étienne Brain, C. Terret and Matti Aapro and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Catherine Oakman

32 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Catherine Oakman Italy 14 686 642 464 190 142 32 1.3k
Matthew D. Burstein United States 7 492 0.7× 640 1.0× 363 0.8× 303 1.6× 75 0.5× 12 1.1k
Yuee Teng China 25 491 0.7× 578 0.9× 941 2.0× 273 1.4× 83 0.6× 86 1.6k
Naruto Taira Japan 23 436 0.6× 796 1.2× 400 0.9× 338 1.8× 204 1.4× 144 1.5k
Giorgia Marisi Italy 23 616 0.9× 478 0.7× 603 1.3× 233 1.2× 230 1.6× 71 1.4k
Deepak Kilari United States 18 281 0.4× 558 0.9× 300 0.6× 466 2.5× 73 0.5× 110 1.1k
Denis Evoy Ireland 18 507 0.7× 476 0.7× 391 0.8× 190 1.0× 340 2.4× 49 1.3k
Oscar Alabiso Italy 24 280 0.4× 651 1.0× 427 0.9× 450 2.4× 165 1.2× 60 1.5k
Felix E. de Jongh Netherlands 22 385 0.6× 1.2k 1.9× 250 0.5× 448 2.4× 262 1.8× 34 2.1k
Christopher Twelves United Kingdom 18 205 0.3× 630 1.0× 467 1.0× 150 0.8× 126 0.9× 53 1.3k
A. Farris Italy 23 599 0.9× 949 1.5× 287 0.6× 408 2.1× 179 1.3× 81 1.6k

Countries citing papers authored by Catherine Oakman

Since Specialization
Citations

This map shows the geographic impact of Catherine Oakman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine Oakman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine Oakman more than expected).

Fields of papers citing papers by Catherine Oakman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine Oakman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine Oakman. The network helps show where Catherine Oakman may publish in the future.

Co-authorship network of co-authors of Catherine Oakman

This figure shows the co-authorship network connecting the top 25 collaborators of Catherine Oakman. A scholar is included among the top collaborators of Catherine Oakman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine Oakman. Catherine Oakman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Bachelot, Thomas, NU Lin, Sara A. Hurvitz, et al.. (2020). 293P Impact of tucatinib on progression free survival in patients with HER2+ metastatic breast cancer and stable or active brain metastases. Annals of Oncology. 31. S359–S360. 9 indexed citations
3.
Peate, Michelle, Sian K. Smith, Victoria Pye, et al.. (2017). Assessing the usefulness and acceptability of a low health literacy online decision aid about reproductive choices for younger women with breast cancer: the aLLIAnCE pilot study protocol. Pilot and Feasibility Studies. 3(1). 31–31. 12 indexed citations
4.
5.
Biganzoli, Laura, Luca Boni, Elena Zafarana, et al.. (2012). Evaluation of the cardiovascular health study (CHS) instrument and the Vulnerable Elders Survey-13 (VES-13) in elderly cancer patients. Are we still missing the right screening tool?. Annals of Oncology. 24(2). 494–500. 26 indexed citations
6.
Galardi, Francesca, Catherine Oakman, Silvia Cappadona, et al.. (2012). Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in early breast cancer patients. The Breast. 21(3). 336–342. 12 indexed citations
7.
Fernandez‐Cuesta, Lynnette, Catherine Oakman, Priscila Falagan-Lotsch, et al.. (2012). Prognostic and predictive value of TP53mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. Breast Cancer Research. 14(3). R70–R70. 46 indexed citations
8.
Biganzoli, Laura, Hans Wildiers, Catherine Oakman, et al.. (2012). Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). The Lancet Oncology. 13(4). e148–e160. 399 indexed citations
9.
Tenori, Leonardo, Catherine Oakman, Wederson M. Claudino, et al.. (2012). Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: A pilot study. Molecular Oncology. 6(4). 437–444. 71 indexed citations
10.
Oakman, Catherine, Erica Moretti, Giulia Pacini, Libero Santarpia, & Angelo Di Leo. (2011). Triple negative breast cancer: a heterogeneous subgroup denned by what it is not. European Journal of Cancer. 47. S370–S372. 9 indexed citations
11.
Oakman, Catherine, Erica Moretti, Francesca Galardi, et al.. (2011). Adjuvant systemic treatment for individual patients with triple negative breast cancer. The Breast. 20. S135–S141. 14 indexed citations
12.
13.
Leo, Angelo Di, Erica Moretti, Catherine Oakman, Laura Biganzoli, & Libero Santarpia. (2011). Predictive molecular markers of anthracycline effectiveness in early breast cancer. European Journal of Cancer Supplements. 9(2). 16–21. 1 indexed citations
14.
Oakman, Catherine, Anna Sapino, Caterina Marchiò, et al.. (2010). Chemotherapy with or without trastuzumab. Annals of Oncology. 21. vii112–vii119. 7 indexed citations
15.
Oakman, Catherine, Libero Santarpia, & Angelo Di Leo. (2010). Breast cancer assessment tools and optimizing adjuvant therapy. Nature Reviews Clinical Oncology. 7(12). 725–732. 77 indexed citations
16.
Oakman, Catherine, Giuseppe Viale, & Angelo Di Leo. (2010). Management of triple negative breast cancer. The Breast. 19(5). 312–321. 158 indexed citations
17.
Oakman, Catherine, et al.. (2009). Adjuvant chemotherapy – the dark side of clinical trials Have we learnt more?. The Breast. 18. S18–S24. 3 indexed citations
18.
Oakman, Catherine, Erica Moretti, Francesca Galardi, Libero Santarpia, & Angelo Di Leo. (2009). The role of topoisomerase IIα and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients. Cancer Treatment Reviews. 35(8). 662–667. 25 indexed citations
19.
Oakman, Catherine, Silvia Bessi, Elena Zafarana, et al.. (2009). Recent advances in systemic therapy. New diagnostics and biological predictors of outcome in early breast cancer. Breast Cancer Research. 11(2). 205–205. 59 indexed citations
20.
Moretti, Erica, Catherine Oakman, & Angelo Di Leo. (2009). Predicting anthracycline benefit: have we made any progress?. Current Opinion in Oncology. 21(6). 507–515. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Matthew D. Burstein Breakdown of academic impact, for papers by Yuee Teng Breakdown of academic impact, for papers by Naruto Taira Breakdown of academic impact, for papers by Giorgia Marisi Breakdown of academic impact, for papers by Deepak Kilari Breakdown of academic impact, for papers by Denis Evoy Breakdown of academic impact, for papers by Oscar Alabiso Breakdown of academic impact, for papers by Felix E. de Jongh Breakdown of academic impact, for papers by Christopher Twelves Breakdown of academic impact, for papers by A. Farris
Rankless by CCL
2026